| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 19.2 | 0.3 |
| Profit before tax | -16.2 | -72.0 |
| Net income | -17.4 | -72.0 |
| EPS (diluted, $ a share) | $-0.14 | $-0.61 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +5406.9% |
|---|---|
| Operating margin | -230.6% |
10-Q filed with the SEC, NASDAQ: NAMS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
NewAmsterdam Pharma Co N.V.: key numbers
- Share price
- $19.46Close, Nov 16
- Market cap
- $2.33B
- Shares outstanding
- 119.93MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from NewAmsterdam Pharma Co N.V.
All →NewAmsterdam Pharma Co Financial Results
NewAmsterdam Pharma reported third quarter 2026 financial results and highlighted the European Commission's approval of Ubeslo and Evlarco for hypercholesterolaemia. The company ended the quarter with $643.1 million in cash and expects an interim analysis of its PREVAIL cardiovascular outcomes trial in Q4 2026.
“The third quarter was marked by significant progress across our regulatory and clinical priorities, including the first regulatory approval of obicetrapib worldwide and the initiation of the SPINOZA Phase 2b trial in preclinical Alzheimer’s disease. Looking ahead, we anticipate reaching the predefined event number for the planned PREVAIL interim analysis in the fourth quarter, with the outcome expected in the first quarter of 2027.”
Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma
NewAmsterdam Pharma Co CSO Johannes Jacob Pieter Kastelein Sells $1.26M of Stock
Johannes Jacob Pieter Kastelein, CSO, sold 50,246 shares of NewAmsterdam Pharma Co N.V. at $25.03 a share, worth $1.26M in total on Sep 30, 2026. Shares held after the trade: 69,302 (-42.0%).
- Value
- $1.26M
- Shares
- 50,246
- Price
- $25.03
- Role
- CSO
- Holding change
- -42.0%
- Trade date
- Sep 30, 2026
NewAmsterdam Pharma Co Business Update
NewAmsterdam Pharma has dosed the first participant in its Phase 2b SPINOZA clinical trial, which evaluates obicetrapib in approximately 400 individuals with preclinical Alzheimer’s disease. The study will assess changes in blood-based biomarkers and cognitive measures over a 52-week treatment period. This expansion into Alzheimer's follows biomarker signals observed in the company's Phase 3 BROADWAY trial.
NewAmsterdam Pharma Co Regulatory Approval
NewAmsterdam Pharma and its partner Menarini Group received European Commission marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe FDC) for the treatment of hypercholesterolaemia, marking the first regulatory approval for obicetrapib worldwide. The approval triggers milestone payments to NewAmsterdam in the mid-teens of millions of euros under its existing licensing agreement with Menarini. The company remains eligible for up to €833 million in total milestones plus tiered double-digit royalties on net sales in Europe.
- Counterparty
- Menarini Group